Blog: BETTER THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 7.01 Regulation FD Disclosure.

On September 22, 2022, Better Therapeutics, Inc. (the “Company”) announced that
it has submitted a de novo classification request to the U.S. Food and Drug
Administration seeking marketing authorization for BT-001, the Company’s
investigational prescription digital therapeutic designed to use nutritional
cognitive behavioral therapy to treat type 2 diabetes. A copy of the press
release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 in this Current Report on Form 8-K and
Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number       Description

99.1           Press Release of Better Therapeutics, Inc., dated September 22, 2022.

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s